Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Operations: The Company is a Nevada holding company with operations conducted in the People's Republic of China (PRC) through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. It develops, manufactures, and markets pharmaceutical products (injectables, tablets, capsules) and healthcare products (masks, sanitizers).
Capital Structure: 17,162,771 shares of common stock outstanding as of August 12, 2024. A 1-for-5 reverse stock split was effective March 6, 2024.
Key Financial Metrics
| Metric (Six Months Ended June 30) | 2024 | 2023 |
|---|---|---|
| Revenue | $2,294,782 | $3,058,152 |
| Cost of Revenue | $3,600,192 | $3,026,889 |
| Gross Profit (Loss) | $(1,305,410) | $31,263 |
| Operating Loss | $(2,307,573) | $(853,787) |
| Net Loss | $(2,394,022) | $(1,069,005) |
| Loss Per Share (Basic/Diluted) | $(0.16) | $(0.65) |
| Cash and Cash Equivalents (End of Period) | $739,337 | $901,910 |
| Total Assets | $14,261,233 | $16,469,200 |
| Total Liabilities | $6,852,711 | $9,014,579 |
| Stockholders' Equity | $7,408,522 | $7,454,621 |
Liquidity & Debt:
- Working Capital: Negative working capital of approximately $0.74 million (Current Assets $3.97M vs. Current Liabilities $4.71M).
- Debt: Includes lines of credit totaling ~$2.43 million (current and non-current), borrowings from related parties of $1.14 million, and a convertible redeemable note payable of $0.41 million.
- Cash Flow: Net cash used in operating activities was $0.66 million for the six months ended June 30, 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 25.0% year-over-year (YoY) for the six months ended June 30, 2024. This was driven by the implementation of China's Centralized Procurement (CP) policies, where competitors passed consistency evaluations and won bids, while the Company's products (e.g., Omeprazole, Vitamin B6) did not qualify, leading to significant sales drops in "Digestive Diseases" (-78%) and "Other" (-77%) categories.
- Gross Margin Deterioration: The Company shifted from a gross profit of $31k in 2023 to a gross loss of $1.31 million in 2024. Gross margin turned negative (-56.9%) due to reduced production volumes increasing idle equipment costs and increased inventory impairments ($411k write-off).
- Increased R&D: Research and development expenses increased to $0.20 million (from $0.05 million YoY) due to efforts in drug consistency evaluation.
- Accounts Receivable: Gross accounts receivable remain high at ~$14.0 million, with 98.1% aged over 720 days. The allowance for doubtful accounts covers 98.2% of gross receivables, leaving a net receivable balance of only $0.25 million.
- Convertible Note Conversions: The Company issued approximately 2.35 million shares of common stock during the period to satisfy redemption notices on its convertible note payable.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has disclosed substantial doubt about the Company's ability to continue as a going concern within one year. This is due to accumulated deficits of $41.7 million, recurring net losses, negative operating cash flows, and current liabilities exceeding current assets.
- Mitigation Plans: Management plans to enhance advance payment sales models, strengthen accounts receivable collection, explore strategic alternatives for nutrition products, and utilize existing property, plant, and equipment as collateral for additional loans. However, these plans are not yet finalized or probable of implementation.
- Regulatory Risks: Operations are heavily dependent on PRC regulations, including the Centralized Procurement (CP) system and consistency evaluation requirements. Failure to pass these evaluations limits market access.
- Internal Controls: The Company identified a material weakness in internal controls over financial reporting due to a lack of accounting personnel knowledgeable in U.S. GAAP. Disclosure controls were deemed ineffective as of June 30, 2024.
- Related Party Dependence: The Company relies on advances from its Chairperson/CEO ($1.14 million) for working capital. There is no assurance these advances will continue.
Investor Verification Checklist
- Going Concern Status: Verify the feasibility of management's plans to secure additional financing or generate positive cash flow to sustain operations beyond the next 12 months.
- Receivables Recoverability: Assess the likelihood of collecting the $13.7 million in gross accounts receivable that is over 720 days old, given the 98% allowance already recorded.
- Product Pipeline: Confirm the status of "consistency evaluation" for key products (e.g., Candesartan, Omeprazole) and the timeline for potential inclusion in Centralized Procurement.
- Convertible Note Terms: Review the terms of the Streeterville Capital convertible note, specifically the redemption schedule and the dilution impact of future conversions.
- Related Party Transactions: Monitor the terms and repayment status of the $1.14 million borrowing from the Chairperson/CEO and the $1.25 million compensation payable to the officer.